Value
3.6/10data confidence 83%| Component | Sub-score |
|---|---|
| P/E | 2.7 |
| P/S | 0.0 |
| Fwd P/E | 3.1 |
| PEG | 9.1 |
| Analyst target | 3.0 |
- ▸Forward P/E: 34.5x
- ▸PEG: 0.66
KRYS · Why this verdict
Why Krystal Biotech (KRYS) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Krystal Biotech has built a franchise with wide moat characteristics — 54% net margins, a Rule of 40 score of 65, and a near-perfect Piotroski score of 9 out of 9 — and three consecutive earnings beats confirm the growth trajectory is intact; however, the stock has reached its near-term resistance target with effectively no remaining price headroom, and single-product concentration means any adverse development would impact the entire revenue base simultaneously.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Net margins of 54%, a Rule of 40 score of 65 — placing the company in the elite tier on combined growth and profitability — and a Piotroski financial strength score of 9 out of 9 reflect a franchise with durable competitive advantages and strong capital efficiency. Quality breakdown | Net margin stays above 45% and the Rule of 40 score remains above 55 for the next four quarters. | →Stable |
| CounterThe wide moat assessment and elite profitability profile are currently concentrated in a single product; a label expansion setback, a competitive entry, or a formulary exclusion could compress both margins and growth simultaneously, rapidly eroding the quality scores that anchor this thesis. | ||
After a miss in the year-ago quarter, the company delivered three consecutive earnings beats through the most recent period, with positive surprises that have averaged well above what analysts modeled, signaling consistent execution above a rising bar. Earnings | Earnings beats continue in at least 2 of the next 3 quarters with positive EPS surprise percentages. | →Stable |
| CounterWith the stock near its 52-week high and the earnings multiple at 32x forward, the bar for a meaningful positive surprise rises each quarter — a near-miss at current multiples could produce an outsized downside price reaction that disproportionately punishes any shortfall. | ||
All material revenue and growth is attributable to a single commercial product, creating a binary risk profile where any adverse regulatory, commercial, or competitive development would impact the entire revenue base with no diversification buffer. Bear case | A second commercial product or material pipeline milestone reduces single-product revenue concentration below 70% of quarterly revenue within 18 months. | →Stable |
| CounterDeep product focus at this stage of a commercial biotech ramp allows management to direct all resources toward market penetration and patient access — premature diversification can dilute both capital and execution, and concentrated businesses with wide moats often outperform diversified ones at similar stages. | ||
The stock has reached its near-term resistance target, with the take-profit level essentially at the current price and no remaining upside from spot — the setup favors patience and a pullback toward a more favorable entry point. Price targets | The stock pulls back toward the $290 support area, restoring a more favorable risk/reward geometry before the next earnings report in approximately 48 days. | →Stable |
| CounterBreakout momentum — a golden cross, RSI at 64, rising on-balance volume, and the stock above all major moving averages — can sustain a price above resistance longer than mean-reversion logic implies, particularly when the underlying business quality is exceptional and short-covering adds fuel. | ||
Short interest stands at 18% of float against a high-quality, beat-streak franchise, creating conditions for a disorderly covering event if a positive catalyst forces short sellers to exit. Risk breakdown | Short interest falls below 10% of float as positions are covered, or the stock moves more than 20% above the current resistance level on a squeeze. | →Stable |
| CounterAn 18% short position from investors who are aware of the single-product concentration, rich forward multiple, and stock near its 52-week high may reflect an informed directional thesis rather than a mispriced carry — the squeeze risk is real but so is the bear logic that underlies the elevated short. | ||
Net margins of 54%, a Rule of 40 score of 65 — placing the company in the elite tier on combined growth and profitability — and a Piotroski financial strength score of 9 out of 9 reflect a franchise with durable competitive advantages and strong capital efficiency.
→StableQuality breakdown
- Expectation
- Net margin stays above 45% and the Rule of 40 score remains above 55 for the next four quarters.
CounterThe wide moat assessment and elite profitability profile are currently concentrated in a single product; a label expansion setback, a competitive entry, or a formulary exclusion could compress both margins and growth simultaneously, rapidly eroding the quality scores that anchor this thesis.
After a miss in the year-ago quarter, the company delivered three consecutive earnings beats through the most recent period, with positive surprises that have averaged well above what analysts modeled, signaling consistent execution above a rising bar.
→StableEarnings
- Expectation
- Earnings beats continue in at least 2 of the next 3 quarters with positive EPS surprise percentages.
CounterWith the stock near its 52-week high and the earnings multiple at 32x forward, the bar for a meaningful positive surprise rises each quarter — a near-miss at current multiples could produce an outsized downside price reaction that disproportionately punishes any shortfall.
All material revenue and growth is attributable to a single commercial product, creating a binary risk profile where any adverse regulatory, commercial, or competitive development would impact the entire revenue base with no diversification buffer.
→StableBear case
- Expectation
- A second commercial product or material pipeline milestone reduces single-product revenue concentration below 70% of quarterly revenue within 18 months.
CounterDeep product focus at this stage of a commercial biotech ramp allows management to direct all resources toward market penetration and patient access — premature diversification can dilute both capital and execution, and concentrated businesses with wide moats often outperform diversified ones at similar stages.
The stock has reached its near-term resistance target, with the take-profit level essentially at the current price and no remaining upside from spot — the setup favors patience and a pullback toward a more favorable entry point.
→StablePrice targets
- Expectation
- The stock pulls back toward the $290 support area, restoring a more favorable risk/reward geometry before the next earnings report in approximately 48 days.
CounterBreakout momentum — a golden cross, RSI at 64, rising on-balance volume, and the stock above all major moving averages — can sustain a price above resistance longer than mean-reversion logic implies, particularly when the underlying business quality is exceptional and short-covering adds fuel.
Short interest stands at 18% of float against a high-quality, beat-streak franchise, creating conditions for a disorderly covering event if a positive catalyst forces short sellers to exit.
→StableRisk breakdown
- Expectation
- Short interest falls below 10% of float as positions are covered, or the stock moves more than 20% above the current resistance level on a squeeze.
CounterAn 18% short position from investors who are aware of the single-product concentration, rich forward multiple, and stock near its 52-week high may reflect an informed directional thesis rather than a mispriced carry — the squeeze risk is real but so is the bear logic that underlies the elevated short.
Per-dimension breakdown
Quality
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 6.6 |
| ROA | 6.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 5.0 |
| FCF quality | 4.7 |
| Moat | 7.6 |
| Rule of 40 | 9.5 |
| Piotroski F | 10.0 |
- ▸Strong margins: 54%
- ▸Earnings quality warning: 61% FCF/NI
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 32% YoY
Momentum
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.1 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 77)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.8 |
| Analyst rating | 8.0 |
| Price target | 4.4 |
- ▸Light analyst coverage (9.0) — signal dampened
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Notable insider selling — $15,599,712 (0.152% of mkt cap)
Peer rank
5.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.4 |
| quality rank | 8.9 |
| growth rank | 5.7 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.6 |
| support resistance | 0.3 |
| 52w position | 9.9 |
Risk (lower is worse)
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.8 |
| days to cover | 0.0 |
| volatility | 3.7 |
| put call | 8.8 |
| implied vol | 6.0 |
| max pain risk | 3.0 |
| beta | 9.8 |
| debt equity | 6.7 |
- ▸Short squeeze setup: 18% short, quality 7.5
- ▸Above max pain $260
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Downgraded from BUY WAIT — price $354.20 has reached target $349.37. No upside to wait for.
Engine technical detail
verdict_path:
L4:PATH_C2_GARP_WAIT|SANITY:WAIT+price>=TPPassed (7)
- MOMENTUM:4.8>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:39d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.1=NEGATIVE
Warning (1)
- MOMENTUM:4.8<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
-1.11
Upside
-16.7%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The C-path quality+growth combination triggered the HOLD_IF_HOLDING verdict: quality 7.9 and growth 10.0 both clear their thresholds, with asymmetric R:R of -1.11 supporting the read.
The strongest dimensions are Growth at 10.0, Quality at 7.9, and Catalyst at 6.3; the weakest are Insider at 3.4, Technical at 3.6, and Value at 3.6. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -1.11 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Net margins of 54%, a Rule of 40 score of 65 — placing the company in the elite tier on combined growth and profitability — and a Piotroski financial strength score of 9 out of 9 reflect a franchise with durable competitive advantages and strong capital efficiency.
Trip ifNet margin falls below 40% or Rule of 40 score drops below 50 for 2 consecutive quarters.
- P2After a miss in the year-ago quarter, the company delivered three consecutive earnings beats through the most recent period, with positive surprises that have averaged well above what analysts modeled, signaling consistent execution above a rising bar.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P3All material revenue and growth is attributable to a single commercial product, creating a binary risk profile where any adverse regulatory, commercial, or competitive development would impact the entire revenue base with no diversification buffer.
Trip ifA second commercial product accounts for more than 30% of quarterly revenue for 2 consecutive quarters.
- P4The stock has reached its near-term resistance target, with the take-profit level essentially at the current price and no remaining upside from spot — the setup favors patience and a pullback toward a more favorable entry point.
Trip ifStock closes above $360 and sustains that level for 4 consecutive weeks, establishing a new base above prior resistance.
- P5Short interest stands at 18% of float against a high-quality, beat-streak franchise, creating conditions for a disorderly covering event if a positive catalyst forces short sellers to exit.
Trip ifShort interest falls below 8% of float, indicating the squeeze setup has materially dissipated.